IP Library Granted Patent US 7,442,796
Granted Patent B2
US 7,442,796 · App. 10/554,586 · Granted Oct 28, 2008

Compounds for the treatment of metabolic disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,442,796
App. No.
10/554,586
Granted
Oct 28, 2008
Kind
B2
Abstract

Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyper-lipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; m is 0 to 4; q is 0 or 1; t is 0 or 1; R 2 is alkyl having from 1 to 3 carbon atoms; R 3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalendy bound to the remainder of the compound of formula (I) by a ring carbon; and R 1 is hydrogen or alkyl having 1 or 2 carbon atoms. Alternatively, when R 1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula (I).

Claims (17)

1. A biologically active agent, wherein the agent is a compound of the formula:

wherein

n is 1 or 2;

m is 0 to 4;

q is 0 or 1;

t is 0 or 1;

R 2 is alkyl having from 1 to 3 carbon atoms;

R 3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;

A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or

cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or

a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and

R 1 is hydrogen or alkyl having 1 or 2 carbon atoms;

or when R 1 is hydrogen, a pharmaceutically acceptable salt of the compound.

2. The biologically active agent of claim 1 , wherein n is 1; q is 0; t is 0; R 3 is hydrogen; and

A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy.

3. The biologically active agent of claim 1 , wherein A is 2,6-dimethylphenyl.

4. The biologically active agent of claim 3 , [3-(2,6-Dimethylbenzyloxy)-phenyl]-oxoacetic acid.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2023
From: WELLSTAT THERAPEUTICS CORPORATION
To: PHARMA CINQ, LLC
Reel/Frame 065474/0475 →
RELEASE OF SECURITY INTEREST Recorded Jan 21, 2021
From: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
To: WELLSTAT THERAPEUTICS CORPORATION
Reel/Frame 055056/0891 →
SECURITY AGREEMENT Recorded Sep 18, 2013
From: WELLSTAT THERAPEUTICS CORPORATION
To: PDL BIOPHARMA, INC.
Reel/Frame 031227/0227 →
SECURITY AGREEMENT Recorded Aug 16, 2013
From: WELLSTAT THERAPEUTICS CORPORATION
To: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 031029/0875 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2006
From: VENTURE MANAGEMENT ALLIANCE LLC
To: CDC INVESTMENTS, LLLP
Reel/Frame 017707/0189 →